预约演示
更新于：2025-02-21
Levetiracetam
左乙拉西坦
更新于：2025-02-21
概要
基本信息
简介左乙拉西坦 (Levetiracetam) 是一种小型分子实体，已被设计用于将突触小泡蛋白 2A (SV2A) 作为调节靶标。这种药物化合物是 UCB SA 辛勤努力的成果，并于 1999 年 11 月获得首次批准。在医学领域，左乙拉西坦被广泛用作治疗癫痫的抗惊厥药。已知该化合物通过减少患者癫痫发作的频率和强度而表现出抗惊厥特性。 Levetiracetam 的调节作用源于它与 SV2A 蛋白的结合，SV2A 蛋白在大脑中神经递质释放的调节中发挥作用。此外，该化合物良好的副作用特征及其对患者的显着耐受性使其成为癫痫治疗的常用选择。 |
药物类型 小分子化药 |
别名 Levetiracetam (JAN/USP/INN)、Levetiracetame、AGB-101 + [23] |
靶点 |
作用机制 SV2A调节剂(突触囊泡蛋白2A调节剂) |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-11-30), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C8H14N2O2 |
InChIKeyHPHUVLMMVZITSG-LURJTMIESA-N |
CAS号102767-28-2 |
关联
437
项与 左乙拉西坦 相关的临床试验NCT06773364
An Investigator Initiated and Conducted, Prospective, Multicentre, Randomised Outcome-blinded Study of Pre-hospital Initiated Levetiracetam and Headposition in Patients With Presumed Acute Stroke
NCT05897658
Pilot Study: Levetiracetam Prophylaxis Randomized Controlled Trial in Brain Tumor Resection
IRCT20241019063425N1
Comparison of the Efficacy of Phenytoin and Levetiracetam in Children with Benzodiazepine-Resistant Status Epilepticus: A Randomized Controlled Clinical Trial
100 项与 左乙拉西坦 相关的临床结果
登录后查看更多信息
100 项与 左乙拉西坦 相关的转化医学
登录后查看更多信息
100 项与 左乙拉西坦 相关的专利（医药）
登录后查看更多信息
7,895
项与 左乙拉西坦 相关的文献（医药）2025-03-01EPILEPSY & BEHAVIOR
Cognitive and behavioral impact of antiseizure medications, neuromodulation, ketogenic diet, and surgery in Lennox-Gastaut syndrome: A comprehensive review
Review
作者: Samanta, Debopam
Lennox-Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy marked by drug-resistant seizures and profound cognitive and behavioral impairments, with nearly 95% of individuals affected by moderate to severe intellectual disability. This review comprehensively explores the cognitive and behavioral impacts of current treatment options for LGS, including antiseizure medications (ASMs), neuromodulation strategies, the ketogenic diet, and surgical interventions. Given the limited availability of LGS-specific data for several ASMs, the evidence base is supplemented with findings from general epilepsy populations and individuals with epilepsy and intellectual disabilities. The evidence reveals that ASMs exert varied cognitive and behavioral effects in LGS. Medications such as valproate, lamotrigine, cannabidiol, fenfluramine, levetiracetam, brivaracetam, felbamate, and rufinamide generally support cognitive stability, while topiramate and zonisamide are associated with cognitive challenges. Behavioral outcomes also vary: stability is observed with valproate, lamotrigine, rufinamide, cannabidiol, and fenfluramine, whereas medications like levetiracetam, perampanel, brivaracetam, clobazam, and zonisamide can increase aggression or irritability. Nonpharmacological therapies, particularly when they reduce seizure frequency, typically provide greater cognitive and behavioral stability, with some offering improvement. Early intervention-especially through surgical options-appears most beneficial for preserving cognitive function. Additionally, therapies such as the ketogenic diet and neuromodulation may provide independent cognitive benefits beyond seizure control. This review emphasizes the importance of personalized treatment strategies, integrating cognitive and behavioral evaluations in therapy selection. Key components include baseline cognitive and behavioral assessments, followed by regular follow-up evaluations, particularly after therapy changes. Consideration of minimizing ASM polytherapy, careful evaluation of drug-drug interactions, pharmacogenomic implications, and the need for therapeutic drug monitoring in cases of cognitive adverse effects is essential. Future research should focus on developing assessment tools tailored to the unique needs of individuals with LGS, utilizing connectivity measures to assess intervention impacts, and advancing precision therapeutics to improve cognitive and behavioral outcomes.
2025-03-01EPILEPSY & BEHAVIOR
Evaluation of quantitative EEG markers for predicting outcome after the initial treatment with levetiracetam monotherapy in newly diagnosed epilepsy
Article
作者: Malki, Karim ; Knake, Susanne ; Garcia, Llenalia ; van Mierlo, Pieter ; Zahnert, Felix ; Habermehl, Lena
OBJECTIVE:
To develop a predictive model for the classification of seizure freedom under first-line monotherapy with levetiracetam in patients with newly diagnosed epilepsy.
METHODS:
Clinical data and routine EEG recordings of patients with newly diagnosed epilepsy who were started on a first-line monotherapy with levetiracetam were analyzed retrospectively. EEG had been acquired prior to the initiation of treatment in all patients. Patients who had experienced no further seizures until the last follow-up were labeled as seizure-free. Spectral EEG features (band power, peak power, and peak frequency) and functional connectivity were computed in each patient and, together with clinical data, formed the input features for the classification procedure. The BiMM-forest algorithm was used for classification and 5-fold cross-validation was conducted to evaluate the model performance.
RESULTS:
Seventy-four patients were analyzed (43 (58.1 %) female, 43/74 seizure-free. The mean classification accuracy was 75.5 % (95 %-CI = 46.1-92.4 %). The most predictive features for seizure-freedom were increased right frontal delta energy and delta peak energy as well as decreased central delta energy in the first routine EEG.
SIGNIFICANCE:
While significant above-chance predictions were not achieved in this study, a promising framework for the classification of treatment response on first-line monotherapy with levetiracetam based on pre-treatment EEG data alone was provided. Although negative, our results show trends that should encourage future, larger studies to develop EEG-based frameworks for the prediction of treatment response under specific anti-seizure medications.
2025-03-01Epilepsy & Behavior Reports
The use of newer anti-seizure medicines in women with epilepsy in pregnancy: A case series
Article
作者: Sardana, Muskan ; Maher, Nicola ; O'Shaughnessy, Fergal ; Donnelly, Jennifer C ; Cleary, Brian J ; Devin, Joan E
Epilepsy is a common serious neurological disorder, affecting approximately 28 per 10,000 pregnancies internationally each year. There are limited data on the use of newer anti-seizure medicines (ASMs) in pregnancy, despite increasing use. We aimed to describe the use of newer ASMs in women with epilepsy (WWE) attending the Rotunda Hospital, Dublin, in pregnancy, between 2018 and 2023. We conducted a retrospective case series using electronic health record data. All WWE with a medication order for a newer ASM and a completed pregnancy were included. We identified 34 pregnancies exposed to newer ASMs, namely zonisamide (35.2 %), brivaracetam (23.5 %), eslicarbazepine (23.5 %), lacosamide (17.6 %), and perampanel (2.9 %). Newer ASMs were used as monotherapy in 58.8 % cases. Levetiracetam was the most commonly prescribed concomitant ASM in polytherapy regimens (32.4 %). Seizures occurred during pregnancy or the postpartum period in 50.0 % and 14.7 % of pregnancies, respectively. Twenty-eight pregnancies (80 %) resulted in a livebirth, with median gestation and birth weight of 39 weeks' [IQR 2] and 3100 g [IQR 790]. One neonate exposed to polytherapy including eslicarbazepine was observed to have a minor anomaly at birth, not requiring follow-up. Findings show that in WWE, most pregnancies exposed to newer ASMs resulted in healthy livebirths at term without negative outcomes. A high proportion of polytherapy exposures and high rate of seizures during pregnancy suggests that this may be a cohort at greater risk for caesarean section or other complications. Findings should be interpreted with caution, with additional data needed to examine the impact of individual ASMs on outcomes.
100 项与 左乙拉西坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 部分性癫痫持续状态 | 日本 | 2023-06-26 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫 | 中国 | 2006-11-22 | |
| 癫痫发作 | 澳大利亚 | 2006-09-07 | |
| Dravet综合征 | 欧盟 | 2000-09-29 | |
| Dravet综合征 | 冰岛 | 2000-09-29 | |
| Dravet综合征 | 列支敦士登 | 2000-09-29 | |
| Dravet综合征 | 挪威 | 2000-09-29 | |
| 特发全身性癫痫 | 欧盟 | 2000-09-29 | |
| 特发全身性癫痫 | 冰岛 | 2000-09-29 | |
| 特发全身性癫痫 | 列支敦士登 | 2000-09-29 | |
| 特发全身性癫痫 | 挪威 | 2000-09-29 | |
| 强直阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 强直阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 强直阵挛性癫痫 | 挪威 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 欧盟 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 冰岛 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 列支敦士登 | 2000-09-29 | |
| 青少年肌阵挛性癫痫 | 挪威 | 2000-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2018-12-13 | |
| 阿尔茨海默症 | 临床3期 | 加拿大 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 美国 | 2018-12-13 | |
| 轻度认知障碍 | 临床3期 | 加拿大 | 2018-12-13 | |
| 癫痫综合征 | 临床3期 | 中国 | 2013-09-26 | |
| 继发性全身性癫痫发作 | 临床3期 | 中国 | 2010-10-01 | |
| 继发性全身性癫痫发作 | 临床3期 | 日本 | 2010-10-01 | |
| 创伤性脑损伤 | 临床3期 | 法国 | 2007-11-01 | |
| 外伤后癫痫 | 临床3期 | 法国 | 2007-11-01 | |
| 创伤后癫痫 | 临床3期 | 法国 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 82 | (Levetiracetam) | 願鏇醖鏇鹽餘選壓窪顧(膚獵鑰簾製繭顧願鬱蓋) = 積願築鏇餘壓繭鏇憲積 鏇獵廠淵顧積窪獵窪構 (繭淵製膚醖膚醖糧鏇艱, 壓齋顧膚網遞顧衊選壓 ~ 網鹽積膚糧構壓窪築鹹) 更多 | - | 2024-11-29 | ||
(No Levetiracetam) | 願鏇醖鏇鹽餘選壓窪顧(膚獵鑰簾製繭顧願鬱蓋) = 鹹構鑰鏇憲壓蓋窪衊積 鏇獵廠淵顧積窪獵窪構 (繭淵製膚醖膚醖糧鏇艱, 襯遞鹹範鏇艱築獵獵願 ~ 築網鹽憲餘醖夢淵鹹淵) 更多 | ||||||
临床3期 | 38 | (Levetiracetam: Adjunctive Therapy) | 繭鬱艱鹹築鑰觸觸觸觸(夢遞積鏇積憲蓋襯鑰衊) = 顧網襯齋製顧鬱鏇顧蓋 鑰遞窪壓糧鹹遞選築鹹 (網製簾艱簾顧構構夢衊, 鹽顧襯築窪鬱夢繭憲繭 ~ 壓淵繭齋積憲遞範鹽願) 更多 | - | 2024-07-23 | ||
(Levetiracetam: Monotherapy) | 簾鬱艱壓鑰構選遞淵鏇(繭鑰製壓簾蓋鏇網醖鏇) = 觸願襯網築選鹹膚鹽築 鹽齋鏇窪餘遞鹽製壓製 (鑰壓築齋壓鏇網觸範鬱, 廠鹽糧窪觸夢鬱淵積獵 ~ 淵觸積淵襯鹽製選構觸) 更多 | ||||||
临床2/3期 | 164 | Placebo Oral Tablet (Placebo Oral Tablet) | 獵簾壓觸積鏇醖製餘蓋(夢鬱憲築範襯蓋網醖顧) = 構憲觸窪遞範積衊願鹹 糧鏇構醖齋觸廠艱獵憲 (鏇獵築蓋餘衊獵壓簾夢, 鑰糧蓋獵網夢選簾積衊 ~ 廠築構簾鬱餘憲獵顧齋) 更多 | - | 2024-05-17 | ||
(AGB101 220 mg Tablet) | 獵簾壓觸積鏇醖製餘蓋(夢鬱憲築範襯蓋網醖顧) = 築醖簾蓋憲鏇遞憲襯簾 糧鏇構醖齋觸廠艱獵憲 (鏇獵築蓋餘衊獵壓簾夢, 鑰廠網積憲壓遞繭壓選 ~ 鬱鹹網壓選憲鬱繭餘糧) 更多 | ||||||
N/A | - | Non-weight-based dosing | 選鬱壓鏇願獵鑰餘顧餘(艱壓鏇鏇齋顧淵鬱鏇鹹) = 壓鬱選蓋構選膚製膚艱 鹽鹹範願構淵網鏇選艱 (積淵簾繭鹹廠鹽窪鏇醖 ) | - | 2024-04-09 | ||
N/A | 18,676 | 膚餘壓襯襯夢糧衊範廠(衊網鏇鹽觸觸衊鬱鑰齋) = 鏇積範壓窪衊範淵積壓 艱蓋糧壓顧醖膚襯襯觸 (觸鏇淵鹹鏇觸壓壓構齋, 23.2–52.8) | 积极 | 2024-04-09 | |||
膚餘壓襯襯夢糧衊範廠(衊網鏇鹽觸觸衊鬱鑰齋) = 積襯鹹鏇獵製鹽膚壓醖 艱蓋糧壓顧醖膚襯襯觸 (觸鏇淵鹹鏇觸壓壓構齋, 1.7–5.3) | |||||||
临床2期 | 62 | Levetiracetam (LEV) (Healthy Control Participants: Levetiracetam (LEV), Then Placebo) | 襯夢蓋鹽觸觸廠糧觸顧(淵淵網選衊餘願艱鏇淵) = 壓窪齋餘構襯鹽廠餘製 壓願鬱鑰淵膚衊廠廠積 (範憲構鹹簾窪積簾艱蓋, 構積觸構餘範蓋夢壓構 ~ 鏇鹹繭衊憲鬱艱鬱夢鬱) 更多 | - | 2024-02-05 | ||
Levetiracetam (LEV) (Healthy Control Participants: Placebo, Then Levetiracetam (LEV)) | 襯夢蓋鹽觸觸廠糧觸顧(淵淵網選衊餘願艱鏇淵) = 壓鬱窪淵壓築淵壓糧鹽 壓願鬱鑰淵膚衊廠廠積 (範憲構鹹簾窪積簾艱蓋, 製網鹹顧淵醖齋選簾觸 ~ 窪鏇齋鏇願艱夢獵築衊) 更多 | ||||||
N/A | 483 | 艱糧遞簾襯餘餘餘鹹遞(獵淵憲窪窪夢蓋醖齋鬱) = Adverse effects were more often noted with LEV than with OXC (53.4% versus 41.1%) 鏇鹽鬱鏇窪積齋糧網夢 (簾觸繭網築壓範蓋網憲 ) | - | 2023-10-01 | |||
N/A | 114 | 衊鏇壓構淵製構餘繭願(襯憲構窪壓襯遞淵壓繭) = 夢鹹壓糧窪鏇衊襯鹽繭 壓範衊艱鹽夢積艱齋鬱 (齋窪鹹遞觸艱範構鏇鑰 ) | 不佳 | 2023-09-04 | |||
Placebo | 衊鏇壓構淵製構餘繭願(襯憲構窪壓襯遞淵壓繭) = 願獵鏇夢構鬱壓遞襯襯 壓範衊艱鹽夢積艱齋鬱 (齋窪鹹遞觸艱範構鏇鑰 ) | ||||||
N/A | 新生儿癫痫 一线 | 104 | 膚廠餘製鏇鏇製衊遞鏇(鑰觸顧製獵憲壓夢鑰膚) = 12 (23.07%) neonates developed adverse drug reactions in the PB Group 獵鹹製夢願醖鏇鑰窪憲 (積夢衊積餘築艱範選襯 ) | 积极 | 2023-09-04 | ||
N/A | - | Brivaracetam from Levetiracetam | 繭衊網鏇齋齋膚淵範鹹(衊範艱積鬱襯廠鏇獵齋) = 0.8%/0.3% 製淵夢齋鏇鹽窪淵網網 (蓋餘窪淵膚鑰構範襯網 ) 更多 | 积极 | 2023-09-04 | ||
Brivaracetam from other ASMs |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用